Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Acquired by Barclays PLC
Barclays PLC has significantly increased its stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 353.6% in Q4, now owning 54,166 shares valued at $531,000. Other institutional investors also acquired stakes during the same period. Ginkgo Bioworks stock rose 6.4% to $7.88, with a market cap of $457.02 million. The company reported a quarterly loss of $1.58 EPS, missing estimates, but revenue was $48.32 million, exceeding expectations. Analysts predict a -10.02 EPS for the current fiscal year.
Barclays PLC increased its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 353.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 54,166 shares of the company's stock after purchasing an additional 42,224 shares during the period. Barclays PLC owned approximately 0.09% of Ginkgo Bioworks worth $531,000 at the end of the most recent reporting period.
Get Ginkgo Bioworks alerts:
Several other hedge funds and other institutional investors have also made changes to their positions in DNA. SBI Securities Co. Ltd. acquired a new stake in Ginkgo Bioworks during the 4th quarter worth $29,000. KBC Group NV acquired a new position in Ginkgo Bioworks during the fourth quarter worth $31,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Ginkgo Bioworks in the fourth quarter valued at about $46,000. Palumbo Wealth Management LLC acquired a new position in Ginkgo Bioworks during the fourth quarter worth about $144,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Ginkgo Bioworks during the 4th quarter worth approximately $154,000. Hedge funds and other institutional investors own 78.63% of the company's stock.
Ginkgo Bioworks Stock Up 6.4 %
Ginkgo Bioworks stock opened at $7.88 on Friday. The firm has a market capitalization of $457.02 million, a PE ratio of -0.60 and a beta of 1.29. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $5.00 and a 52 week high of $38.58. The firm's 50-day simple moving average is $7.13 and its 200 day simple moving average is $9.09.
Ginkgo Bioworks (NYSE:DNA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.35). Ginkgo Bioworks had a negative return on equity of 58.54% and a negative net margin of 298.78%. The business had revenue of $48.32 million during the quarter, compared to analyst estimates of $38.70 million. On average, research analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current fiscal year.
Ginkgo Bioworks Profile
(Free Report)Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Further Reading
- Five stocks we like better than Ginkgo Bioworks
- 3 Warren Buffett Stocks to Buy Now
- IBM's AI Offensive: Assessing IBM's Path to Renewed Growth
- What Makes a Stock a Good Dividend Stock?
- Rockwell Automation: Tailwinds From Onshoring U.S. Production
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Is Energy Transfer Undervalued or a Value Trap?
Want to see what other hedge funds are holding DNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Ginkgo Bioworks Right Now?
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
